EXPEREO
31.7.2024 09:01:32 CEST | Business Wire | Press release
Over one third (35%) of global enterprises are struggling to retain or attract crucial skills in AI, data and automation, which is threatening their optimistic AI ambitions. This is according to research from an IDC InfoBrief, commissioned by Expereo, Enterprise Horizons 2024* which highlights a critically low supply of AI expertise, despite AI now being considered as the biggest priority for CIOs across the world.
The research of 650 technology leaders in global enterprises across Europe, US and APAC showed that not only are enterprises struggling to attract or retain crucial talent, but their current external technology partners are not aligned to their AI ambitions either. 29% of global CIOs said their current external technology partners do not have the right capabilities in place to support AI initiatives, and 28% of global respondents feel regional variations in ability to implement AI initiatives is a key challenge.
The other leading obstacle to fulfilling AI ambitions include navigating AI governance and ethics (36%). This refers to ongoing challenges such as regulation, trust and data protection when it comes to using AI tools in a business setting. This is another concern which could be eased with support and guidance by experienced AI talent.
The survey found that 42% of CIOs also believe that training for new ways of working, a result of AI, is one of the biggest IT challenges in supporting remote and hybrid workers, and 39% said that understanding how employees use AI is now a concern.
Network performance and flexibility are additionally among the key factors preventing companies from implementing AI at scale. When asked what prevents or limits their organization’s networks from supporting large data or AI projects, 38% of global respondents said network performance, such as application responsiveness or latency, and 38% of global respondents also said their networks’ inability to scale flexibly on demand.
What’s more, networking talent was cited as the second hardest area to recruit for, with 36% of global respondents citing it as a key challenge. In fact, networking talent was even harder to recruit for than data, AI and automation, suggesting that it’s more than just AI talent that organisations are struggling to onboard, it’s the core infrastructure talent too.
In spite of these challenges, 32% of CIOs are moving forward with caution with AI implementation, and 44% are excited and ready to take on AI initiatives. Just less than one in 10 global enterprises (8%) are not ready to take on AI at all. When asked how long it will be until their organization implement AI initiatives, more than a quarter of global respondents (36%) expect to implement cybersecurity AI initiatives within the next 12 months.
Ben Elms, CEO, Expereo, comments:
“CIOs need to keep pace with market innovations, customer expectations and fierce competition when it comes to AI, while ensuring they are adopting the technology responsibly and effectively, without cutting corners. This is a difficult act to balance, and without the necessary skills in place, driven by competition for AI and core networking talent, CIOs should look to outsource crucial expertise, and partner with the right technology providers that can offer the local expertise and growth initiatives that work for them.
“Networking technology, data strategies and wider tech infrastructure are all key areas which run adjacent to AI initiatives, which must also not be ignored.”
For the full *IDC InfoBrief, doc #EUR252162924, June 2024 please visit: https://www.expereo.com/whitepapers/enterprise-horizons-2024
About Expereo
Expereo is the world leading intelligent internet company that connects people, places, and things anywhere. Solutions include Global Internet, SD-WAN/SASE, and Enhanced Internet. With an extensive global reach, Expereo is the trusted partner of 60% of Fortune 500 companies. It powers enterprise and government sites in more than 190 countries, with the ability to connect to any location worldwide, working with over 2,300 partners to help customers improve productivity and empowering their networks and cloud services with the agility, flexibility, and value of the Internet, with optimal network performance.
Expereo was acquired in Feb 2021, by Vitruvian Partners which acquired a majority shareholding from Seven2.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731662333/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom